Vizsgálati helyszín
A-Shine s.r.o.
Plzen 3, 301 00, CsehországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 17lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis25 vizsgálat
- 2. fázis10 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult17 vizsgálat
- Toboroz12 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- AbbVie3 vizsgálat
- Bristol-Myers Squibb3 vizsgálat
- Intra-Cellular Therapies, Inc.3 vizsgálat
- Neurocrine Biosciences3 vizsgálat
- Boehringer Ingelheim International GmbH2 vizsgálat
- és még 19
Futó vizsgálatok
Fut, nem toboroz
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· 3. fázis· Newron Pharmaceuticals S.p.A.· Forrás
Toboroz
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397· 3. fázis· Cybin IRL Limited· Forrás
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Meghívásos bevonás
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700· 2. fázis· Seaport Therapeutics· Forrás
Meghívásos bevonás
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105· 3. fázis· Cybin IRL Limited· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240· 2. fázis· Seaport Therapeutics· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044· 3. fázis· Vanda Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595· 3. fázis· Definium Therapeutics US, Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624· 3. fázis· Neurocrine Biosciences· Forrás
Toboroz
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression
2023-505268-12-00· 3. fázis· Compass Pathfinder Limited· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· 3. fázis· AbbVie· Forrás
Lezárult
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· 3. fázis· Janssen Cilag International· Forrás
Lezárult
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· 3. fázis· Neumora Therapeutics Inc.· Forrás
Lezárult
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine
2023-507942-10-00· 2. fázis· Boehringer Ingelheim International GmbH· Forrás
Lezárult
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039· 3. fázis· Neumora Therapeutics, Inc.· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Lezárult
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· 3. fázis· AbbVie· Forrás
Lezárult
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· 3. fázis· Neurocrine Biosciences Inc.· Forrás
Lezárult
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· 3. fázis· Janssen Cilag International· Forrás
Lezárult
A Trial of GH001 in Patients With Treatment-resistant Depression
NCT05800860· 2. fázis· GH Research Ireland Limited· Forrás
Lezárult
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
2022-500538-27-00· 2/3. fázis· Otsuka Pharmaceutical Development And Commercialization Inc.· Forrás
Lezárult
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239· 2. fázis· Recognify Life Sciences· Forrás
Lezárult
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study
2024-511560-93-00· 3. fázis· Boehringer Ingelheim International GmbH· Forrás
Lezárult
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· 2. fázis· Inmune Bio, Inc.· Forrás
Lezárult
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· 3. fázis· Neurocrine Biosciences· Forrás
Lezárult
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek